3 reports

  • 14.7 PHARMACYTE BIOTECH INC. 14.7.1 Key Facts
  • THREATS

The global pancreatic cancer therapy market is expected to reach US$ 4,056.4 Mn in 2025 from US$ 2,011.2 Mn in 2017. The market is estimated to grow with a CAGR of 8.1% from 2018-2025. The growth of the pancreatic cancer therapy market is primarily attributed to the increase in number of therapies launched in the market.The development...

  • Cancer
  • World
  • Forecast
  • Market Size
  • PharmaCyte Biotech, Inc.
  • FEB 24, 2016: PHARMACYTE BIOTECH ON SCHEDULE FOR 2016 CANCER CLINICAL TRIAL IN PANCREATIC CANCER
  • NOV 01, 2016: PHARMACYTE BIOTECH REQUESTS PRE-IND MEETING WITH FDA FOR ITS PANCREATIC CANCER CLINICAL TRIAL

Summary PharmaCyte Biotech Inc (PharmaCyte), formerly Nuvilex Inc, is a clinical stage biotechnology company that develops and commercializes treatments for cancer and diabetes.The company offers technology is used for the treatment of advanced and inoperable pancreatic cancer and diabetes. It develops cell-in-a-box...

  • Biotech
  • Cancer
  • Pharmaceutical
  • Therapy
  • PharmaCyte Biotech, Inc.
  • PRODUCTS UNDER DEVELOPMENT BY COMPANIES, H1 2018
  • Toll Like Receptor 8 (CD288 or TLR8) - Therapeutics Development

In this trial, ## patients with PASI scores of ##. ## or greater will be randomized ##:##:##:## to receive weekly subcutaneous doses of IMO-## at ##. ##, ##. ##, or ##. ## mg/ kg/ week or placebo for ## weeks.

  • Cancer
  • Lymphoma
  • Pharmaceutical
  • Therapy
  • Idera Pharmaceuticals, Inc.